Arcutis Biotherapeutics Q1 Earnings Call Highlights
MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) reported first-quarter 2026 net product revenues of $105.4 million, a 65% increase versus the same period last year, as the company pointed to continued demand growth for its topical therapy ZORYVE and progress across a “grow, expand, build” strategy that includ
NASDAQ:ARQT